Stopping adalimumab associated with high rates of low disease activity in RA

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • 3 y after discontinuing adalimumab (ADA), 4 in 5 patients with rheumatoid arthritis (RA) in this observational study remained in low disease activity (LDA), with fewer adverse events than those who continued ADA.
  • Continuing ADA led to higher rates of LDA as well as of adverse event...